Patient preference study using discrete choice experiment for Multiple Myeloma patients in Korea

Not Applicable

Recruiting

• Conditions: Neoplasms

• Registration Number: KCT0009395
• Lead Sponsor: The Catholic University of Korea, Seoul St. Mary's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Patient:

1. Individuals aged 18 and above.
2. Those who can read and understand documents written in Korean.
3. Patients who have been diagnosed with multiple myeloma by a healthcare professional and fall into one of the following treatment stages: newly diagnosed and scheduled for treatment, undergoing 1st or 2nd line treatment, or in a relevant condition after treatment. Recurrent/resistant patients requiring additional treatment for multiple myeloma after the 3rd line of treatment.
4.Must sign an Informed Consent Form (ICF) allowing data collection and confirmation of evidence based on local requirements.

Caregiver:

1. Individuals aged 18 and above.
2. Those who can read and understand documents written in Korean.
3. Individuals providing care for a multiple myeloma patient and well-informed about the treatment options for the condition.
The survey includes questions about whether the caregiver currently lives with the patient or is the primary family member providing financial support to the patient.
4. Must sign an Informed Consent Form (ICF) allowing data collection and confirmation of evidence based on local requirements.

Physician:

1. Those who can read and understand documents written in Korean.
2. Individuals with more than 3 years of experience in treating multiple myeloma patients.
3. Those who diagnose/monitor more than 50 multiple myeloma patients annually.
4. Individuals with over 3 years of experience discussing multiple myeloma treatment and management with other healthcare professionals such as hematologists/oncologists, 'multiple myeloma specialist' (key opinion leaders)/conference speakers.
5. Must agree to participate in the study before the online survey.

Exclusion Criteria

N/A

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relative Importance of Attributes: What is the perceived relative importance of various treatment attributes according to Korean multiple myeloma stakeholders (patients, caregivers, physicians)?;Risk/Benefit Balance: What is the risk/benefit balance characterizing the decision-making of Korean multiple myeloma patients and caregivers?;Willingness to Pay: How much are Korean multiple myeloma patients and caregivers willing to trade off one attribute for another?;Understanding of Patient Treatment Progression: How do treatment-related attributes (such as the relative importance of attributes and willingness to pay) differ between newly diagnosed multiple myeloma patients/caregivers and those with a substantial treatment history in Korea?;Segmentation: How are decision-makers segmented, and what characteristics can predict their choices?;Minimal Important Difference (MID): How do patients define meaningful treatment benefits?

Secondary Outcome Measures

Name	Time	Method
Quality of Life: How does the treatment scenario impact the quality of life?